VitaDAO is a community-owned collective dedicated to funding and advancing longevity science that can improve people's lives. With your support we can turn the tide on age related disease.
Connect with an active community of longevity scientists and get funding for your work.
Contribute skills to help us advance longevity science. VitaDAO is owned and built by our community.
Everything you need to know about the governance token that powers our community
Funding Deployed
Research Projects Funded
Liquid Funds
Community Members
ImmuneAGE Bio is the first drug discovery platform company focused on immune system rejuvenation. ImmuneAGE rejuvenates hematopoietic stem cells (HSCs) from the bone marrow based on a geroscience screening platform enabled by a new ‘StemSupply’ method achieving >1000x expansion of HSCs.
.png)
Senescent cells accumulate with age and are associated with numerous diseases. Dr. Amit Sharma’s team have identified senescence-specific cell surface biomarkers which will act as targets for developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells aiming to precisely and safely eliminate senescent cells in vivo.
Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age and is thought to be a driver of Alzheimer’s and other age-related diseases. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.
What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.
Get involved today - support the science of tomorrow.
We support researchers at every stage of their career and provide funding to qualifying projects.
Help us build the world’s leading longevity DAO and get rewarded for your skills.
Beat age related disease by empowering the research bringing new therapeutics to market.
